by Mike Masnick
Wed, Jan 5th 2011 9:05am
A few months back, we noted that the PubPat Foundation was seeking to invalidate eight patents held by Abbott Labs in the US concerning the HIV/AIDS drug ritonavir (branded as Norvir). PubPat noted that there was significant prior art that should have precluded those patents from ever being granted. While we'll probably be waiting a long time to hear about that, over in India, it appears that the Patent Office has decided to come right out and reject Abbott's attempts to patent ritonavir, noting that it did not appear to involve the necessary "inventive step" to constitute an invention. Not surprisingly, Abbott is not happy about all this, and is looking at its options -- meaning not only should you expect to see a lawsuit, but just wait for lobbyists to start complaining about how India doesn't live up to its "international obligations" in protecting international patents.
If you liked this post, you may also be interested in...
- Google Lobbied Against Real Net Neutrality In India, Just Like It Did In The States
- Why Patent Trolls Love East Texas... And Why Congress Needs To Fix It
- Could A Hedge Fund Manager Trying To Short Stocks Of Pharma Companies With Bad Patents Derail Patent Reform?
- Giant Pharma Company Claims Releasing Data On Drug Safety Is Illegal As It's Confidential And 'Commercially Sensitive'
- Another Boost For Generics: Brazilian Judge Annuls Patent On Key AIDS Drug